The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset ...
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources … ...
Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...
Five months after cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond ...
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...
Black Diamond has got itself a longer runway, securing a licensing deal with French pharmaceutical group Servier for an early-stage small molecule cancer drug Black Diamond backburnered last year. The ...
NEW YORK – Servier has signed a global licensing agreement with Black Diamond Therapeutics to develop and commercialize BDTX-4933 for treating RAF- and RAS-mutant solid tumors, including non-small ...
When putting together graphic designs or editing photos, opaque backgrounds on images can be a hindrance - so knowing how to make the background transparent in Photoshop is a useful trick.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback